Breast cancer: my three previously published books

Breast cancer: my three previously published books

● MicroRNAs in Breast Cancer

(Nova Publishers, http://www.novapublishers.com/, 2010)

Book Description:

MicroRNAs, or miRNAs, are a recently discovered class of small regulatory RNAs that influence the stability and translational efficiency of target messenger RNAs (mRNAs). Alterations in miRNA expression are associated with an increasing number of biological processes, including breast cancer. The study of miRNAs is a rapidly developing field that could considerably change our vision of breast cancer biology. This book offers an insight into our current knowledge of human miRNAs, with a specific interest for breast cancer.

Table of Contents:

Chapter 1. Introduction

Chapter 2. Detection and Measurement of miRNAs

Chapter 3. miRNA-Related Bioinformatics Tools

Chapter 4. miRNAs of Importance in Breast Cancer

Chapter 5. Clinical Potential of miRNAs in Breast Cancer

Chapter 6. Human miRNAs: Genes, Names, Loci, Sequences, Clusters

Index

Softcover: ISBN: 978-1-61668-438-9

Ebook: ISBN: 978-1-61668-498-3

● Molecular Therapy of Breast Cancer: Classicism Meets Modernity

(Nova Publishers, http://www.novapublishers.com/, 2009)

Book Description:

Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. Despite their proven efficacy, classical therapies are, however, unable to cure metastatic breast cancer and are often associated with significant toxicity and side-effects, due to a wide spectrum of action. During the last years, our increasing knowledge of the molecular pathways underlying cancer development has led to the introduction of new drugs, of which most are directed towards very specific targets. Rather than to be used as single agents, these “modern” compounds could ultimately be combined with classical molecules.

Here are described nearly 150 drugs that are currently used in routine therapy or are in clinical trials in breast cancer patients. From the classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin, epirubin, docetaxel, paclitaxel…, to the more recently introduced ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab…, they also include capecitabine, gemcitabine, trastuzumab, bevacizumab, fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of tumor-induced osteolysis, insulin-like growth factor-I receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many others.

This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity.

Table of Contents:

Chapter 1. Introduction

Chapter 2. Selective estrogen receptor modulators (SERMs) and down-regulators (SERDs)

Chapter 3. Aromatase inhibitors

Chapter 4. Agents inducing ovarian suppression

Chapter 5. Antimetabolites

Chapter 6. Alkylating agents

Chapter 7. Anthracyclines

Chapter 8. Microtubule-binding agents

Chapter 9. Topoisomerase inhibitors

Chapter 10. HER family inhibitors

Chapter 11. Angiogenesis inhibitors

Chapter 12. Insulin-like growth factor-I receptor inhibitors

Chapter 13. RAS-RAF-MEK-ERK pathway inhibitors

Chapter 14. Ubiquitin-proteasome system inhibitors

Chapter 15. Histone deacetylases inhibitors

Chapter 16. Mitotic inhibitors

Chapter 17. Inhibitors of heat-shock proteins 90 and 27

Chapter 18. PI3K/AKT/mTOR pathway inhibitors

Chapter 19. Cyclooxygenase-2 inhibitors

Chapter 20. Poly(ADP-ribose) polymerase (PARP)-1 inhibitors

Chapter 21. Tumor-induced osteolysis inhibitors

Chapter 22. Vaccines and immunomodulators

Chapter 23. Varia

Index

Hardcover: ISBN: 978-1-60741-593-0

Ebook: ISBN: 978-1-60876-726-7

● Tumor Suppressor Genes in Breast Cancer

(Nova Publishers, http://www.novapublishers.com/ 2008)

Book Description:

Breast cancer is characterized by the accumulation of genetic alterations, including point mutations and loss of entire DNA regions (“loss of heterozygosity” or LOH). Among genes that are affected by such events, the “tumor suppressor genes” (TSGs) have a peculiar interest since they often occupy pivotal positions in regulatory networks that control the cell cycle and/or encompass various signal transduction cascades. While a number of genes have been suggested as candidate TSGs in breast cancer, only a few of them have been confirmed in this status. They include TP53, BRCA1, BRCA2 and are mainly involved in the control of DNA repair, cell proliferation, apoptosis and signaling. Some TSGs are linked to familial (hereditary) forms of breast cancer. The exact definition of what is a TSG is still debated. Recently, genes not affected by mutation or even LOH, but occasionally methylated have been considered as TSGs.

Table of Contents:

Preface

1. Introduction

2. Inactivating Events: LOH, Point Mutations, Methylation

3. TP53: A Major TSG in (Breast) Cancer

4. BRCA1 and BRCA2, Major TSGs in Familial Breast Cancer

5. Detailed Information on Candidate TSGs

6. Conclusions

Acknowledgments

References

Index

Softcover: ISBN: 978-1-60456-326-9